Volume 86, Issue 3, Pages 625-637 (September 2014) No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end points in hemodialysis patients  Christian D. Peters, Krista D. Kjaergaard, Jens D. Jensen, Kent L. Christensen, Charlotte Strandhave, Ida N. Tietze, Marija K. Novosel, Bo M. Bibby, Lars T. Jensen, Erik Sloth, Bente Jespersen  Kidney International  Volume 86, Issue 3, Pages 625-637 (September 2014) DOI: 10.1038/ki.2014.69 Copyright © 2014 International Society of Nephrology Terms and Conditions

Figure 1 Inclusion and exclusion criteria have been published previously.30 Briefly, the main inclusion criteria were urine output >300ml/day, dialysis vintage <1 year, and left ventricular (LV) ejection fraction >30%. Kidney International 2014 86, 625-637DOI: (10.1038/ki.2014.69) Copyright © 2014 International Society of Nephrology Terms and Conditions

Figure 2 The graph shows the fraction of patients in the study as a Kaplan–Meier plot with time from baseline as timescale. Completion was estimated by Kaplan–Meier curves and difference between the two groups by log-rank test. A total of 26 (placebo/ARB: 11/15) patients dropped out during the study period (for causes, see Figure 1) and the log-rank test for equality of completion functions yielded P=0.34. Thus, time of dropout was not significantly different in the two groups. ARB, angiotensin II receptor blocker. Kidney International 2014 86, 625-637DOI: (10.1038/ki.2014.69) Copyright © 2014 International Society of Nephrology Terms and Conditions

Figure 3 Development of brachial BP, central BP, augmentation index, and PWV. AIx, augmentation index; ARB, angiotensin II receptor blocker; BP, blood pressure; PWV, pulse wave velocity based on direct distance (see Materials and Methods section for further details). *0.05>P≥0.01 versus baseline within the placebo or ARB group; **0.01>P≥0.001 versus baseline within the placebo or ARB group; ***P<0.001 versus baseline within the placebo or ARB group. Kidney International 2014 86, 625-637DOI: (10.1038/ki.2014.69) Copyright © 2014 International Society of Nephrology Terms and Conditions

Figure 4 Correlations between intermediate cardiovascular end points. The symbol ‘x’ indicates placebo, ‘•’ indicates ARB, ‘¦’ indicates regression line for placebo, ‘|’ indicates regression line for ARB, and ‘Δ’ indicates change (12 months–baseline). ARB, angiotensin II receptor blocker; LVM index, left ventricular mass index; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; PWV, pulse wave velocity based on direct distance. Kidney International 2014 86, 625-637DOI: (10.1038/ki.2014.69) Copyright © 2014 International Society of Nephrology Terms and Conditions

Figure 5 Development of NT-proBNP as well as parameters reflecting activity of the autonome nervous system. ARB, angiotensin II receptor blocker; LF/HF, low-frequency power/high-frequency power; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; SDNN, s.d. of the N–N interval. *0.05>P≥0.01 versus baseline within the placebo or ARB group; **0.01>P≥0.001 versus baseline within the placebo or ARB group; †0.05>P≥0.01 placebo versus ARB; ↕‡Indicate that the curves were assumed parallel (model 2). The constant mean difference (placebo–ARB) in log(p-noradrenaline) with 95% confidence interval was 0.55 (0.12–0.98) log(nmol/l); P=0.002. Kidney International 2014 86, 625-637DOI: (10.1038/ki.2014.69) Copyright © 2014 International Society of Nephrology Terms and Conditions